Juvenile Arthritis News

A subset of patients with Still’s disease develop drug reactions with eosinophilia and systemic symptoms to interleukin-1 and IL-6 inhibitors, with strong associations among those with common HLA-DRB1*15 haplotypes, according to data.

The FDA has approved secukinumab for the treatment of active psoriatic arthritis in patients aged 2 years and older, and for active enthesitis-related arthritis in those aged 4 years and older.

Results from the 2021 Medical Specialties Matching Program reveal that pediatric rheumatology fellowship programs filled less than 70% of their available slots, according to the American College of Rheumatology.

The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023.

In this video from ACR Convergence 2021, Kathryn Dao, MD, discusses a presentation based on a podcast, “Take a Pain Check,” for teenagers with rheumatic disease.

Patients with rare autoimmune rheumatic diseases have a 54% increased risk for COVID-19 infection, and more than twice the risk for COVID-19 death, versus the general population, according to data published in Rheumatology.

The COVID-19 pandemic brought with it a significant decrease in autoimmunity laboratory testing, first rheumatology visits and diagnoses from 2019 to 2020, according to Italian data published in The Journal of Rheumatology.

Secukinumab is efficacious in children and adolescents with psoriatic arthritis and enthesitis-related arthritis, resulting in a significantly longer time to flare versus placebo, according to data presented at ACR Convergence 2021.

Initial biologic therapy is now the most common treatment for children with systemic juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry, according to data presented at ACR Convergence 2021.

Early, aggressive treatment with a biologic alongside a conventional DMARDs for juvenile idiopathic arthritis achieved clinically inactive disease at 24 months more frequently than other strategies, said a presenter at ACR Convergence 2021.